The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization

Hepatology

Volumn 48, Issue 5, 2008, Pages 1517-1527

  Zeng, Wenjiao ^a,c   Gouw, Annette S H ^a   van den Heuvel, Marius C ^a   Zwiers, Peter J ^a   Zondervan, Pieter E ^b   Poppema, Sibrand ^a   Zhang, Nong ^c   Platteel, Inge ^a   de Jong, Koert P ^a   Molema, Grietje ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SINUSOID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; AGED; CANCER INVASION; GENETICS; LIVER TUMOR; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; ANGIOPOIETIN-2; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 56149106773     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22490     Document Type: Article

References (44)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer 2001;37(Suppl 8):S4-S66.
2. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. HEPATOLOGY 2007;45:42-52.
3. Blum HE. Liver cancer. Eur J Gastroenterol Hepatol 2005;17:475-476.
4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235.
5. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S188.
6. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
7. Fathers KE, Stone CM, Minhas K, Marriott JJ, Greenwood JD, Dumont DJ, et al. Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am J Pathol 2005;167:1753-1762.
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
9. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. HEPATOLOGY 2006;43:1267-1275.
10. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151-167.
11. Zeng WJ, Gouw AS, van den Heuvel MC, Poppema S, de Jong KP. Angiogenic characteristics in hepatocellular carcinomas: A comparison of HCCs in cirrhotic and non-cirrhotic livers and influence of grading [Abstract]. HEPATOLOGY 2006;44(Suppl 1):506A.
12. Yu Q. The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncol 2005;1:475-484.
13. Cohen HT, McGovern FJ. Renal-cell carcinoma.N Engl J Med 2005;353: 2477-2490.
14. Kuldo JM, Westra J, Asgeirsdottir SA, Kok RJ, Oosterhuis K, Rots MG, et al. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005;289:C1229-C1239.
15. de Jong KP, Vermeulen PB, van Marck E, Boot M, Gouw AS. Endothelial cell apoptosis in the context of quantification of angiogenesis in solid human adenocarcinomas: A novel double immunolabelling technique to identify endothelial cell apoptosis. Eur J Cancer 2006;42:97-100.
16. Baldewijns MM, Thijssen VL, Van den Eynden GG, Van Laere SJ, Bluekens AM, Roskams T, et al. High-grade dear cell renal cell carcinoma has a higher angiogenic activity than low-gradc renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile, Br J Cancer 2007;96:1888-1895.
17. Karrar A, Broome U, Uzunel M, Qureshi AR, Sumitran-Holgersson S. Human liver sinusoidal endothelial cells induce apoptosis in activated T cells: A role in tolerance induction. Gut 2007;56:243-252.
18. Mathonner M, Descottes B, Valleix D, Labrousse F, Truffinet V, Denizot Y. Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma. World J Gastroenterol 2006;12:3782-3783.
19. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, et al. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 2005; 11: 960-963.
20. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeurn JH, et al. Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003;16:552-557.
21. Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006;12:4241-4245.
22. Mitsuhashi N, Shimizu H, Ohtstika M, Wakabayashi Y, Ito H, Kimura F, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. HEPATOLOGY 2003;37: 1105-1113.
23. Paradis V, Bieche I, Dargere D, Laurendeau I, Nectoux J, Degort C, et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003;124:651-659.
24. Amaoka N, Osada S, Kanematsu M, Imai H, Tomita H, Tokuyama Y, et al. Clinicopathological features of hepatocellular carcinoma evaluated by vascular endothelial growth factor expression. J Gastroenterol Hepatol 2007;22:2202-2207.
25. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-345.
26. Yoshiji H, Kuriyama S, Noguchi R. Yoshii J, Ikenaka Y, Yanase K, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005;54:1768-1775.
27. An FQ, Matsuda M, Fujii H, Matsumoto Y. Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 2000;126:153-160.
28. Straub AC, Stolz DB, Ross MA, Hernandez-Zavala A, Soucy NV, Klei LR, et al. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. HEPATOLOGY 2007;45:205-212.
29. Lee JS, Semela. D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte? HEPATOLOGY 2007; 45:817-825.
30. Leenders WP, Kustets B, Verrijp K, Maass C, Wesseling P, Heerschap A, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004; 10:6222-6230.
31. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007;170:1-15.
32. Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, et al. Correlations between cyclooxygenase-2 expression and angiogenic factors in primary rumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 2007;37:679-685.
33. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007; 97:1432-1440.
34. Abou-Alfa GK Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced heparocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
35. Llovet M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF. Sorafenib in advanced hepatocellular carcinoma. New Eng J Med 2008; 359:378-390.
36. Zhu AX, Sahani DV, di Tomaso E, Duda D, Sindhwani V, Yoon SS, et al. A phase II study on sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007;25(Suppl):4637.
37. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006;131:1208-1217.
38. Liu L, Can Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858.
39. Moon WS, Park HS, Yu KH, Park MY, Kim KR Jang KY, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma. implications for angiogenesis. Hum Pathol 2006;37:1324-1332.
40. Thomas MB, Chadha R, Glover K, Wang Y, Morris J, Brown T, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-1067.
41. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2005; 102:3389-3394.
42. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, et al. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005;11:8557-8563.
43. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. HEPATOLOGY 2008;47: 1211-1222.
44. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008;14:1-14.